Nachrichten zur Alnylam Pharmaceuticals Inc. Aktie

Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch

…

Alnylam Pharmaceuticals: RNAi-Pionier mit bahnbrechenden Medikamenten

Revolutionäre Technologie : Alnylam nutzt RNA-Interferenz (RNAi), um gezielt krankheitsverursachende Proteine zu blockieren, was besonders für schwere genetische Krankheiten…

Alnylam Pharmaceuticals: Kursziel gesteigert

Charlotte (www.aktiencheck.de) - Rating-Update: Die Analysten von BofA Securities stufen die Aktie von Alnylam Pharmaceuticals Inc. (ISIN: US02043Q1076, WKN: A0CBCK, Ticker-Symbol:…

Alnylam Pharmaceuticals: Biotech-Konzern überprüft fast alle Kästchen für Vutrisiran - Aktienanalyse

London (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von Barclays: Barclays nimmt in einer aktuellen Aktienanalyse die Aktie von Alnylam Pharmaceuticals Inc. (ISIN: US02043Q1076,…

Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises By Investing.com

Ainylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma rises…

Investing in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago would have delivered you a 234% gain

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money…

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2024 Earnings Call Transcript

…

Alnylam: Kursziel um 74 USD angepasst

Vancouver (www.aktiencheck.de) - Rating-Update: Die Analysten von Canaccord Genuity stufen die Aktie von Alnylam Pharmaceuticals Inc. (ISIN: US02043Q1076, WKN: A0CBCK, Ticker-Symbol:…

Alnylam Pharmaceuticals: Sehr positive HELIOS-B-Topline-Ergebnisse für Amvuttra - Kursziel erhöht - Aktienanalyse

New York (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von J.P. Morgan Securities: Jessica Fye, Analystin von J.P. Morgan Securities, erhöht das Kursziel für…

Alnylam Pharmaceuticals: Kursziel gesteigert

Charlotte (www.aktiencheck.de) - Rating-Update: Die Analysten von BofA Securities stufen die Aktie von Alnylam Pharmaceuticals Inc. (ISIN: US02043Q1076, WKN: A0CBCK, Ticker-Symbol:…

Alnylam Pharmaceuticals: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Morgan Stanley stufen die Aktie von Alnylam Pharmaceuticals Inc. (ISIN: US02043Q1076, WKN: A0CBCK,…

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

Alnylam Pharmaceuticals (ALNY) and Alimera Sciences, Inc. (ALIM) are in the spotlight following study and merger updates, respectively.…

Alnylam Pharmaceuticals: Kurszielanhebung

New York (www.aktiencheck.de) - Rating-Update: Ritu Baral, Analyst von TD Cowen, stuft die Aktie von Alnylam Pharmaceuticals Inc. (ISIN: US02043Q1076, WKN:…

Alnylam Pharmaceuticals: Große Marktchance - Aktienanalyse

London (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von Barclays: Die Analysten von Barclays stufen die Aktie von Alnylam Pharmaceuticals Inc. (ISIN: US02043Q1076, WKN:…

Alnylam Pharmaceuticals: Kursziel nach Daten der Phase-3-HELIOS-B-Studie erhöht - Aktienanalyse

Toronto (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von RBC Capital Markets: Luca Issi, Analyst von RBC Capital Markets, hebt in einer aktuellen Aktienanalyse…

Alnylam Pharmaceuticals: Positive Studienergebnisse - Aktienanalyse

New York (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von Chardan: Die Analysten von Chardan erhöhen in einer aktuellen Aktienanalyse ihr Kursziel für die…

Alnylam Pharmaceuticals: "buy"

New York (www.aktiencheck.de) - Rating-Update: Patrick Trucchio, Analyst von H.C. Wainwright & Co, stuft die Aktie von Alnylam Pharmaceuticals Inc. (ISIN:…

Alnylam Pharmaceuticals: Positives Signal - Aktienanalyse

Boston, MA (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalysevon Leerink Partners: Leerink Partners erhöht in einer aktuellen Aktienanalyse das Kursziel für die Aktie von…

Alnylam Pharmaceuticals: HELIOS-B-Daten im Fokus - Kursziel erhöht - Aktienanalyse

San Francisco (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von Wells Fargo Advisors: Die Analysten von Wells Fargo Advisors bewerten die Aktie von Alnylam…

Alnylam Pharmaceuticals: Die Markteinführung von ATTR-CM Mitte 2025? Kaufen! Aktienanalyse

New York (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von der Citigroup: Die amerikanische Großbank Citigroup stuft die Aktie von Alnylam Pharmaceuticals Inc. (ISIN:…

Alnylam Pharmaceuticals: Eines der besten Szenarien - Aktienanalyse

Toronto (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von BMO Capital Markets: Kostas Biliouris, Analyst von BMO Capital Markets, nimmt in einer aktuellen Aktienanalyse…

Alnylam Pharmaceuticals: Großartige HELIOS-B-Daten von Alnylam sehen - Aktienanalyse

St. Louis (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von Stifel: Stifel rät in einer aktuellen Aktienanalyse zum Kauf der Aktie von Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals: Positive Spätphasenergebnisse mit Vutrisiran - Die Aktie explodiert! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Alnylam Pharmaceuticals Inc.…

Ayala Pharmaceuticals files Form 15 to voluntarily deregister and suspend reporting obligations

…

Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company,…

Antisense and RNAi Therapeutics Market Size & Share Envisaged To Reach USD 18.43 Billion By 2032, at 17.8% CAGR Growth: Polaris Market Research

The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It…

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript

…

Alnylam Pharmaceuticals Q4 2023 Earnings Preview

…

Investing in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago would have delivered you a 104% gain

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders might be concerned after seeing the share price drop 13% in...…

Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans

…

Wall Street delves into Alnylam Pharmaceuticals By Investing.com

© Reuters Explore Wall Street’s expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon.…

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,…

Pro Research: Wall Street delves into Alnylam Pharmaceuticals By Investing.com

Pro Research: Wall Street delves into Alnylam Pharmaceuticals…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2023 Earnings Call Transcript

…

Alnylam Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook

…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.(ALNY)

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population  …